The US Food and Drug Administration (FDA) has approved a higher-dose, lower-frequency regimen for glatiramer acetate (Copaxone, Teva Pharmaceutical Industries) in the treatment of relapsing-remitting ...
Copaxone is a prescription drug used to treat different types of multiple sclerosis (MS) in adults. It can cause side effects that range from mild to serious, including injection site reactions, ...
Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced positive results from a study assessing a new lower-volume injection of Copaxone ® (glatiramer acetate) ...
COPAXONE ® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE ® are redness, pain, swelling, ...
AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and ...
JERUSALEM--(BUSINESS WIRE)--Jul. 26, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results